Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Reenaers

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Alimentary Pharmacology & Therapeutics|December 2, 2010
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximabU Kopylov, G J Mantzaris, K H Katsanos, et al.
Journal of Crohn'S & Colitis|February 26, 2022
How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort StudyC Cottron, X Treton, R Altwegg, et al.
Clinical Biochemistry|July 5, 2011
Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patientsO Dewit, T Moreels, F Baert, et al.
Journal of Crohn'S & Colitis|May 5, 2022
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort StudyF Poullenot, A Amiot, M Nachury, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Alimentary Pharmacology & Therapeutics|December 2, 2010
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximabU Kopylov, G J Mantzaris, K H Katsanos, et al.
Journal of Crohn'S & Colitis|February 26, 2022
How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort StudyC Cottron, X Treton, R Altwegg, et al.
Clinical Biochemistry|July 5, 2011
Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patientsO Dewit, T Moreels, F Baert, et al.
Journal of Crohn'S & Colitis|May 5, 2022
Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort StudyF Poullenot, A Amiot, M Nachury, et al.
Pageof 5